Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105158 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Giovanni Duro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Sphingolipids, Glycolipids. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anderson–Fabry disease is a lysosomal storage disorder caused by mutations in the GLA gene, which encodes the enzyme α-galactosidase A. The GLA gene is located on the X-chromosome, causing an X-linked pathology: due to lyonization, female patients usually manifest a variable symptomatology, ranging from asymptomatic to severe phenotypes. The confirmation of the clinical diagnosis of Fabry disease, achieved by measuring α-galactosidase A activity, which is usually the first test used, shows differences between male and female patients. This assay is reliable in male patients with causative mutations in the GLA gene, in whom the enzymatic activity is lower than normal values; on the other hand, in female Fabry patients, the enzymatic activity is extremely variable between normal and pathological values. These fluctuations are also found in female patients’ blood levels of globotriaosylsphingosine (LysoGb3) for the same reason. In this paper, we present a retrospective study conducted in our laboratories on 827 Fabry patients with causative mutations in the GLA gene. Our results show that 100% of male patients had α-galactosidase A activity below the reference value, while more than 70% of female patients had normal values. It can also be observed that almost half of the female patients with pathogenic mutations in the GLA gene showed normal values of LysoGb3 in blood. Furthermore, in women, blood LysoGb3 values can vary over time, as we show in a clinical case presented in this paper. Both these tests could lead to missed diagnoses of Fabry disease in female patients, so the analysis of the GLA gene represents the main diagnostic test for Fabry disease in women to date.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy.
ORCID-Profile: Paolo Colomba
Zitieren
APA
Duro, G., Anania, M., Zizzo, C., Francofonte, D., Giacalone, I., D'Errico, A., Marsana, E. M., & Colomba, P. (2024). Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105158
Vancouver
Duro G, Anania M, Zizzo C, Francofonte D, Giacalone I, D'Errico A, et al. Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105158
BibTeX
@article{Duro2024,
author = {Duro, Giovanni and Anania, Monia and Zizzo, Carmela and Francofonte, Daniele and Giacalone, Irene and D'Errico, Annalisa and Marsana, Emanuela Maria and Colomba, Paolo},
title = {Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify Up to Two Thirds of Female Patients},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105158}
}
EUVIMED